...
首页> 外文期刊>Dermatology Online Journal >Glycopyrrolate-induced craniofacial compensatory hyperhidrosis successfully treated with oxybutynin: report of a novel adverse effect and subsequent successful treatment
【24h】

Glycopyrrolate-induced craniofacial compensatory hyperhidrosis successfully treated with oxybutynin: report of a novel adverse effect and subsequent successful treatment

机译:奥昔布宁成功治疗格隆溴铵诱发的颅面代偿性多汗症:新的不良反应及随后成功治疗的报道

获取原文
           

摘要

Hyperhidrosis, or abnormally increased sweating, is a condition that may have a primary or secondary cause. Usually medication- induced secondary hyperhidrosis manifests with generalized, rather than focal sweating. We report a 32-year-old woman with a history of palmoplantar hyperhidrosis for 15 years who presented for treatment and was prescribed oral glycopyrrolate. One month later, the palmoplantar hyperhidrosis had resolved, but she developed new persistent craniofacial sweating. After an unsuccessful trial of clonidine, oxybutynin resolved the craniofacial hyperhidrosis. To our knowledge, this is the first case of compensatory hyperhidrosis secondary to glycopyrrolate reported in the literature. The case highlights the importance of reviewing medication changes that correlate with new onset or changing hyperhidrosis. It also demonstrates a rare drug adverse effect with successful treatment.
机译:多汗症或出汗异常增加是一种可能是主要或次要原因的疾病。通常,药物引起的继发性多汗症表现为全身性而不是局部出汗。我们报告了一名32岁的女性,有15年的掌hyper多汗病史,她接受治疗并被处方口服格隆溴铵。一个月后,掌plant多汗症已解决,但她出现了新的持续性颅面出汗。在对可乐定进行不成功的试验后,奥昔布宁解决了颅面多汗症。据我们所知,这是文献中报道的继发于格隆溴铵的代偿性多汗症的第一例。该病例强调了审查与新发作或多汗症相关的药物变化的重要性。它还显示了成功治疗后罕见的药物不良反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号